910 related articles for article (PubMed ID: 19858456)
1. CSF biomarkers predict rate of cognitive decline in Alzheimer disease.
Kester MI; van der Vlies AE; Blankenstein MA; Pijnenburg YA; van Elk EJ; Scheltens P; van der Flier WM
Neurology; 2009 Oct; 73(17):1353-8. PubMed ID: 19858456
[TBL] [Abstract][Full Text] [Related]
2. CSF biomarkers in relationship to cognitive profiles in Alzheimer disease.
van der Vlies AE; Verwey NA; Bouwman FH; Blankenstein MA; Klein M; Scheltens P; van der Flier WM
Neurology; 2009 Mar; 72(12):1056-61. PubMed ID: 19307538
[TBL] [Abstract][Full Text] [Related]
3. Value of CSF beta-amyloid1-42 and tau as predictors of Alzheimer's disease in patients with mild cognitive impairment.
Hampel H; Teipel SJ; Fuchsberger T; Andreasen N; Wiltfang J; Otto M; Shen Y; Dodel R; Du Y; Farlow M; Möller HJ; Blennow K; Buerger K
Mol Psychiatry; 2004 Jul; 9(7):705-10. PubMed ID: 14699432
[TBL] [Abstract][Full Text] [Related]
4. Correlation of longitudinal cerebrospinal fluid biomarkers with cognitive decline in healthy older adults.
Stomrud E; Hansson O; Zetterberg H; Blennow K; Minthon L; Londos E
Arch Neurol; 2010 Feb; 67(2):217-23. PubMed ID: 20142530
[TBL] [Abstract][Full Text] [Related]
5. CSF biomarkers predict a more malignant outcome in Alzheimer disease.
Wallin AK; Blennow K; Zetterberg H; Londos E; Minthon L; Hansson O
Neurology; 2010 May; 74(19):1531-7. PubMed ID: 20458070
[TBL] [Abstract][Full Text] [Related]
6. Cerebrospinal fluid biomarkers predict decline in subjective cognitive function over 3 years in healthy elderly.
Stomrud E; Hansson O; Blennow K; Minthon L; Londos E
Dement Geriatr Cogn Disord; 2007; 24(2):118-24. PubMed ID: 17622715
[TBL] [Abstract][Full Text] [Related]
7. Combined rCBF and CSF biomarkers predict progression from mild cognitive impairment to Alzheimer's disease.
Hansson O; Buchhave P; Zetterberg H; Blennow K; Minthon L; Warkentin S
Neurobiol Aging; 2009 Feb; 30(2):165-73. PubMed ID: 17646035
[TBL] [Abstract][Full Text] [Related]
8. CSF tau/Abeta42 ratio for increased risk of mild cognitive impairment: a follow-up study.
Li G; Sokal I; Quinn JF; Leverenz JB; Brodey M; Schellenberg GD; Kaye JA; Raskind MA; Zhang J; Peskind ER; Montine TJ
Neurology; 2007 Aug; 69(7):631-9. PubMed ID: 17698783
[TBL] [Abstract][Full Text] [Related]
9. Cerebrospinal fluid tau/beta-amyloid(42) ratio as a prediction of cognitive decline in nondemented older adults.
Fagan AM; Roe CM; Xiong C; Mintun MA; Morris JC; Holtzman DM
Arch Neurol; 2007 Mar; 64(3):343-9. PubMed ID: 17210801
[TBL] [Abstract][Full Text] [Related]
10. Increasing CSF phospho-tau levels during cognitive decline and progression to dementia.
Andersson C; Blennow K; Almkvist O; Andreasen N; Engfeldt P; Johansson SE; Lindau M; Eriksdotter-Jönhagen M
Neurobiol Aging; 2008 Oct; 29(10):1466-73. PubMed ID: 17512092
[TBL] [Abstract][Full Text] [Related]
11. Longitudinal changes of CSF biomarkers in memory clinic patients.
Bouwman FH; van der Flier WM; Schoonenboom NS; van Elk EJ; Kok A; Rijmen F; Blankenstein MA; Scheltens P
Neurology; 2007 Sep; 69(10):1006-11. PubMed ID: 17785669
[TBL] [Abstract][Full Text] [Related]
12. No association of CSF biomarkers with APOEepsilon4, plaque and tangle burden in definite Alzheimer's disease.
Engelborghs S; Sleegers K; Cras P; Brouwers N; Serneels S; De Leenheir E; Martin JJ; Vanmechelen E; Van Broeckhoven C; De Deyn PP
Brain; 2007 Sep; 130(Pt 9):2320-6. PubMed ID: 17586559
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of cerebrospinal fluid tau/beta-amyloid(42) ratio as diagnostic markers for Alzheimer disease.
Smach MA; Charfeddine B; Ben Othman L; Lammouchi T; Dridi H; Nafati S; Ltaief A; Bennamou S; Limem K
Eur Neurol; 2009; 62(6):349-55. PubMed ID: 19786779
[TBL] [Abstract][Full Text] [Related]
14. Prediction of Alzheimer's disease using a cerebrospinal fluid pattern of C-terminally truncated beta-amyloid peptides.
Höglund K; Hansson O; Buchhave P; Zetterberg H; Lewczuk P; Londos E; Blennow K; Minthon L; Wiltfang J
Neurodegener Dis; 2008; 5(5):268-76. PubMed ID: 18309230
[TBL] [Abstract][Full Text] [Related]
15. Anomalously phosphorylated tau and Abeta fragments in the CSF correlates with cognitive impairment in MCI subjects.
Maccioni RB; Lavados M; Guillón M; Mujica C; Bosch R; Farías G; Fuentes P
Neurobiol Aging; 2006 Feb; 27(2):237-44. PubMed ID: 16399209
[TBL] [Abstract][Full Text] [Related]
16. Diagnosing prodromal Alzheimer's disease: role of CSF biochemical markers.
Parnetti L; Lanari A; Silvestrelli G; Saggese E; Reboldi P
Mech Ageing Dev; 2006 Feb; 127(2):129-32. PubMed ID: 16274728
[TBL] [Abstract][Full Text] [Related]
17. BACE1 activity in cerebrospinal fluid and its relation to markers of AD pathology.
Mulder SD; van der Flier WM; Verheijen JH; Mulder C; Scheltens P; Blankenstein MA; Hack CE; Veerhuis R
J Alzheimers Dis; 2010; 20(1):253-60. PubMed ID: 20164582
[TBL] [Abstract][Full Text] [Related]
18. CSF markers in Alzheimer disease patients are not related to the different degree of cognitive impairment.
Stefani A; Martorana A; Bernardini S; Panella M; Mercati F; Orlacchio A; Pierantozzi M
J Neurol Sci; 2006 Dec; 251(1-2):124-8. PubMed ID: 17097109
[TBL] [Abstract][Full Text] [Related]
19. Episodic memory and speed/attention deficits are associated with Alzheimer-typical CSF abnormalities in MCI.
Nordlund A; Rolstad S; Klang O; Lind K; Pedersen M; Blennow K; Edman A; Hansen S; Wallin A
J Int Neuropsychol Soc; 2008 Jul; 14(4):582-90. PubMed ID: 18577287
[TBL] [Abstract][Full Text] [Related]
20. CSF Abeta42 and tau or phosphorylated tau and prediction of progressive mild cognitive impairment.
Herukka SK; Hallikainen M; Soininen H; Pirttilä T
Neurology; 2005 Apr; 64(7):1294-7. PubMed ID: 15824371
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
